-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.
-
Summary
-
NeuBase Therapeutics, Inc. quarterly Deferred Tax Assets, Operating Loss Carryforwards history and growth rate from Q3 2015 to Q3 2022.
- NeuBase Therapeutics, Inc. Deferred Tax Assets, Operating Loss Carryforwards for the quarter ending September 30, 2022 was $22.5M, a 69.5% increase year-over-year.
Deferred Tax Assets, Operating Loss Carryforwards, Quarterly (USD)
Deferred Tax Assets, Operating Loss Carryforwards, YoY Quarterly Growth (%)